Search

Search Constraints

You searched for: Author/Creator Doyle, Ralph T.

Search Results

1. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Issue 22 (28th October 2021)

4. Icosapent ethyl reduces atherogenic markers in high-risk statin-treated patients with stage 3 chronic kidney disease and high triglycerides. Issue 6 (18th August 2019)

5. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Issue 23 (7th December 2021)

6. Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Issue 3 (15th March 2017)

7. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States. Issue 5 (4th February 2020)

8. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses. Issue 1 (5th January 2021)